Skip to content

Inspection Record

IDT Biologika GmbH — FDA 483 Findings

US FDAInspected 2023-09-08Published 2026-10-26 5 findingsTraining and personnelOther quality systemComputer system validationLaboratory and QC controls

Inspectors Roger F Zabinski · Laurel A BeerThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

GMP training is not conducted on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.

2Other quality system

Lots of licensed products were released by the manufacturer prior to completion of tests for conformity with standards applicable to such product.

3Computer system validation

Backup data is not assured as exact, complete and secure from alteration, erasure or loss through keeping (B)I@)EN LN s9stems Specifically, The firm's Quality Unit including Quality Control Molecular Biology lab manager and IT staff do not perform audits of all GMP lab data including all to ensure adequate controls are in place for all lab systems including the — systems.

4Laboratory and QC controls

The suitability of all testing methods is not verified under actual conditions of use.

5Other quality system

(b) (4) processing areas are deficient regarding the system for monitoring environmental conditions.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

IDT Biologika GmbH company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.